Accelerated Approval: Oncopeptides' Pepaxto Will Test New Expedited Withdrawal Process

 
• By Sue Sutter
  
Feet in ocean
A dispute over interpretation of the OCEAN trial data is at the heart of Oncopeptides' decision to test the waters of US FDA's new expedited withdrawal procedures. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards